A 52 Week Open Label Trial of Memantine for Frontotemporal Lobar Degeneration

Phase 4

Completed

• Conditions: Frontotemporal Lobar Degeneration

• Registration Number: NCT00187525
• Lead Sponsor: University of California, San Francisco

Brief Summary

This is a 52-week, multicenter, open label trial of memantine (Namenda) for frontotemporal lobar degeneration (FTLD). The goal is to determine the safety and tolerability of this FDA-approved medication for Alzheimer's Disease in patients with FTLD. Secondary outcome measures include cognitive batteries, rating scales for activities of daily living and neuropsychiatric symptoms. All patients receive the FDA-approved dose of this medication for Alzheimer's disease.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-05
• Study First Submitted: 2005-09-13
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-16
• Primary Completion: 2005-10
• Study Completion: 2006-10
• Status Verified: 2012-11
• Last Update Submitted: 2012-11-08
• Last Update Posted: 2012-11-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Neary et al. Criteria for Frontotemporal Lobar Degeneration
• Age 40 -80
• CDR < 3 or MMSE > 15
• English Speaking
• Study Partner

Exclusion Criteria

• Concurrent use of antipsychotic drugs or acetylcholinesterase inhibitors

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP